AI assistant
Vir Biotechnology, Inc. — Director's Dealing 2023
May 6, 2023
32538_dirs_2023-05-05_74f9b516-2a94-41b1-a7c9-8f847bba0504.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2023-05-03
Reporting Person: SVF Endurance (Cayman) Ltd (10% Owner)
Reporting Person: SB INVESTMENT ADVISERS (UK) LTD (10% Owner)
Reporting Person: SOFTBANK VISION FUND (AIV M1) L.P. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-03 | Common Stock | S | 83674 | $25.512 | Disposed | 17751051 | Indirect |
| 2023-05-04 | Common Stock | S | 114332 | $25.5498 | Disposed | 17636719 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.29 to $25.95. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.76. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.